Table 4 Response assessment of re-induction therapy.
Re-induction therapy regimen of NR patients | Venetoclax + azacitidine +/– homoharringtonine(n = 12) | Chemotherapy (n = 8) |
|---|---|---|
CR | 58.3% (7) | 50% (4) |
CRi | 8.3% (1) | 0 |
PR | 0 | 13% (1) |
NR | 16.7% (2) | 25% (2) |
CRc | 66.7% (8) | 50% (4) |
ORR | 66.7% (8) | 63% (5) |
Death rate in re-induction therapy | 16.7% (2) | 13% (1) |
